The Shotlee Journal
Browse Shotlee articles about GLP-1 Medications.
Showing 9 / 934 GLP-1 Medications articles
Kris Jenner reveals her embrace of peptide therapy, detailing its benefits for energy and skin, and how it served as an alternative to GLP-1 medications like Ozempic. Explore the growing world of peptide treatments.
From GLP-1 medications to plastic surgery, society faces complex questions about beauty, ethics, and medical resources. Discover the balance between empowerment and pressure.
Kris Jenner recently shared her experience with GLP-1 medications, revealing they made her feel unwell. This opens the door to understanding the nuances of these popular drugs and exploring alternative peptide therapies for weight management and overall health.
Novo Nordisk's Wegovy experienced a remarkable 70% sales volume increase in April after significant price adjustments. This development highlights the growing demand for GLP-1 receptor agonists in weight management and the dynamic shifts within the pharmaceutical market.
Rapid weight loss, often aided by GLP-1 medications like Ozempic and Mounjaro, can lead to significant physical transformations. While celebrated, these changes can sometimes include unwelcome skin laxity, commonly referred to as 'Ozempic Face.' This article delves into the causes, expert opinions, and potential solutions for this growing concern.
New research suggests that the way you eat—whether driven by emotions or external cues—can significantly influence how well GLP-1 medications like Ozempic, Wegovy, and Mounjaro work for weight loss and type 2 diabetes management. Learn what this means for your treatment.
Achieving sustainable weight loss is a journey, not a race. This comprehensive guide offers expert advice on nutrition, exercise, and mindset to help you build healthy habits for life.
CVS Health exceeded earnings expectations, but what does this mean for patients using GLP-1 medications like Ozempic or Wegovy? We break down the financial news and its real-world implications for your healthcare coverage.
A groundbreaking NIH-funded study reveals that emerging GLP-1 weight-loss drugs, including oral options like orforglipron, work by targeting a specific brain reward pathway, distinct from their appetite-suppressing effects. This discovery opens new avenues for understanding and treating conditions beyond weight management.
